Journal
ANNALS OF ONCOLOGY
Volume 12, Issue 4, Pages 509-511Publisher
KLUWER ACADEMIC PUBL
DOI: 10.1023/A:1011194910571
Keywords
dolastatin; LU103793; melanoma; phase II
Categories
Ask authors/readers for more resources
LU103793, a synthetic analogue of dolastatin 15, showed interesting pre-clinical activity in melanoma xenografts. In this phase II multicentre trial, 80 chemotherapy-naive patients with metastatic melanoma received a total of 218 cycles of treatment. The response rate showed one complete and three partial responses of median duration six months (range 3-9.1). Toxicity was moderate, mostly haematological (neutropenia grade 4 in 16%, grade 3 in 3%). There were no significant problems with hypertension or other non-haematological toxicities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available